v3.26.1
License Agreements (Details Narrative) - USD ($)
 3 Months Ended
Mar. 16, 2026
Mar. 31, 2026
License agreement description   During the year ended December 31, 2025, the Company agreed to a request from AlloTera Therapeutics to suspend the AlloTera Therapeutics License for a period of one year from the effective date of the suspension, or until May 29, 2026.
Gross proceeds from upfront license fee $ 3,500,000  
Net proceeds after tax from upfront license fee 2,900,000  
Fair value 3,500,000  
Performance obligation description   The Company identified two distinct performance obligations: (i) the delivery of licensed intellectual property— comprising the licensed patent rights, licensed know-how, a related license to HCW9109, and a technology transfer (collectively, the “Licensed IP”); and (ii) post-transfer development services consisting of an improved cell line and a master cell bank (collectively, the “Services”). The transaction price at inception was $6,650,000, reflecting the $7.0 million in upfront consideration less $350,000 was carved out as a contract liability related to prepaid optional post-transfer services.
Revenues   $ 6,500,000
Contract liability   470,000
Remaining Services consideration   120,000
Prepayment of post transfer services   350,000
Carrying value   3,500,000
Maximum [Member]    
Proceeds from development and regulatory milestone payments $ 16,000,000.0  
Ancillary Service [Member]    
Revenues   13,001
Licensed IP [Member]    
Revenues   6,300,000
Service [Member]    
Revenues   $ 230,000